Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pantoprazole  and Pyridoxamine (PAP) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 26/January/2017, 11.22 pm